Previous 10 | Next 10 |
home / stock / crpof / crpof news
– Q1 2023 sales of $3,500,000 vs $6,172,000 in Q1 2022 – Ended the quarter with $12.6 million in cash allowing funding for planned pipeline development EDMONTON, Alberta, May 25, 2023 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: ...
– Results from the completed Collaborative Health Research Projects (CHRP) study with McMaster University presented at the American Thoracic Society (ATS) International Conference – – Data demonstrated that PGX-processed yeast beta glucan (PGX-YBG) is respirable and...
– Data presented at 2023 Annual Meeting of the Wound Healing Society showed statistically significant results characterizing the in vivo bioactivity of Ceapro’s oat-derived bioactive products on wound healing and tissue regeneration – Tissue treated with Avenanthram...
EDMONTON, Alberta, April 27, 2023 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO, OTCQX: CRPOF) (“Ceapro” or the “Company”) , a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmeti...
– 2022 marks Ceapro’s best performance in Company history with record sales of $18,800,000 compared to $17,200,000 for 2021, representing a 10% increase year over year – Net profit after tax of $4,400,000 for the full year of 2022 compared to $3,400,000 in 2...
EDMONTON, Alberta, March 23, 2023 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosm...
– Oral presentation to highlight unique results from pre-clinical studies characterizing the in vivo bioactivity of Ceapro’s oat-derived bioactive products on angiogenesis, wound healing and tissue regeneration – EDMONTON, Alberta, March 08, 2023 (GLOBE NEWSWI...
EDMONTON, Alberta, Feb. 21, 2023 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”) , a growth-stage biotechnology company focused on the development and commercialization of active ingredients and disruptive technolo...
- Live video webcast presentations with participating companies - FRENCHTOWN, NJ / ACCESSWIRE / January 11, 2023 / JTC Team ("JTC"), a fully integrated corporate communications and investor relations firm, today announced it will host the Virtual Investor 2023 Companies to Watch Event, Jan...
EDMONTON, Alberta, Jan. 10, 2023 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”) , a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic ind...
News, Short Squeeze, Breakout and More Instantly...
TORONTO and EDMONTON, Alberta, June 03, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”) and Ceapro Inc. (TSX-V: CZO) (OTCQX: CRPOF) (“Ceapro”), two innovative biopharmaceutical development companies, ...
– Q1 2024 marked by significant advancement of R&D projects focused on avenanthramide Phase 1-2a clinical study and the processing of yeast beta glucan along with the building of pilot scale units for PGX Technology – Q1 2024 sales of $2,800,000 vs $3,500,0...
Faraday Future Intelligent Electric Inc. (FFIE) is expected to report for Q1 2024 D-Market Electronic Services & Trading (HEPS) is expected to report for Q1 2024 Christian Dior SE ADR (CHDRY) is expected to report for Q1 2024 Check-Cap Ltd. (CHEK) is expected to report $-0.17 for ...